Anchor Investment Management LLC Sells 946 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Anchor Investment Management LLC decreased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 79.1% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 250 shares of the biopharmaceutical company’s stock after selling 946 shares during the quarter. Anchor Investment Management LLC’s holdings in Regeneron Pharmaceuticals were worth $131,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of REGN. Marino Stram & Associates LLC raised its position in shares of Regeneron Pharmaceuticals by 5.3% in the 2nd quarter. Marino Stram & Associates LLC now owns 396 shares of the biopharmaceutical company’s stock worth $208,000 after purchasing an additional 20 shares during the last quarter. Activest Wealth Management increased its stake in Regeneron Pharmaceuticals by 110.5% during the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 21 shares in the last quarter. CX Institutional raised its holdings in Regeneron Pharmaceuticals by 7.9% in the second quarter. CX Institutional now owns 302 shares of the biopharmaceutical company’s stock worth $159,000 after buying an additional 22 shares during the last quarter. Redwood Wealth Management Group LLC lifted its stake in shares of Regeneron Pharmaceuticals by 4.8% in the second quarter. Redwood Wealth Management Group LLC now owns 506 shares of the biopharmaceutical company’s stock worth $266,000 after buying an additional 23 shares in the last quarter. Finally, Princeton Capital Management LLC grew its holdings in shares of Regeneron Pharmaceuticals by 1.9% during the second quarter. Princeton Capital Management LLC now owns 1,240 shares of the biopharmaceutical company’s stock valued at $651,000 after buying an additional 23 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Sanford C. Bernstein upped their price objective on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an “outperform” rating in a research report on Wednesday, August 27th. Morgan Stanley upped their price target on Regeneron Pharmaceuticals from $767.00 to $768.00 and gave the company an “equal weight” rating in a report on Friday. Truist Financial began coverage on Regeneron Pharmaceuticals in a research report on Monday, November 24th. They set a “buy” rating and a $798.00 price objective on the stock. Citigroup boosted their target price on Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Finally, Bank of America raised their price target on shares of Regeneron Pharmaceuticals from $543.00 to $627.00 and gave the company an “underperform” rating in a report on Wednesday, October 29th. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $779.45.

Regeneron Pharmaceuticals Stock Up 1.5%

Shares of REGN stock opened at $752.62 on Tuesday. The company’s fifty day moving average price is $667.78 and its 200-day moving average price is $593.79. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $790.98. The company has a market capitalization of $79.10 billion, a price-to-earnings ratio of 18.02, a PEG ratio of 2.12 and a beta of 0.37. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm had revenue of $3.75 billion during the quarter, compared to analysts’ expectations of $3.57 billion. During the same quarter last year, the business posted $12.46 earnings per share. The firm’s revenue was up .9% on a year-over-year basis. Sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Shareholders of record on Thursday, November 20th were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend was Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 8.43%.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Christine A. Poon sold 6,500 shares of the business’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the sale, the director directly owned 2,352 shares of the company’s stock, valued at $1,538,843.04. The trade was a 73.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Jason Pitofsky sold 431 shares of the business’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the transaction, the vice president directly owned 4,233 shares in the company, valued at approximately $2,757,503.19. This represents a 9.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.